Establishment Labs Strengthens Leadership Team with the Appointment of Nicolas Maurer as Chief Commercial Officer

NEW YORK, NY (PRWEB) JUNE 12, 2017

Establishment Labs, a global medical device company focused on aesthetic technologies with a strong emphasis on product development and innovation, announced today that Nicolas Maurer has been appointed Chief Commercial Officer effective immediately. Maurer will oversee the company’s commercial sales and marketing initiatives, establishing Motiva Implants® as one of the most vibrant brands in the industry.

“Nicolas brings extensive business expertise and innovative marketing leadership to Establishment Labs,” said Juan José Chacón-Quirós, CEO and founder of Establishment Labs. “He is well recognized for building some of the most successful brands in global cosmetics. I am confident that Nicolas’ insight and industry knowledge will help us elevate the Motiva brand, increase both plastic surgeon and consumer specific requests for Motiva products, and drive revenue growth over the long term. We are delighted to welcome his inspiration and leadership to our team.”

Maurer’s career includes several entrepreneurial start-up ventures as well as 17 years with German cosmetics corporation Beiersdorf AG, which owns globally recognized brands such as NIVEA, Eucerin, LaPrairie, Elastoplast and Aquaphor, where he managed multiple product launches and led the development of strategies across a number of marketing channels.

As Corporate Vice President of Marketing at Beiersdorf AG, Maurer was responsible for growing the skincare product portfolio worldwide. Prior, he managed Beiersdorf’s U.S. brand portfolio. His award-winning campaigns led to numerous recognitions from Walmart, CVS, Target and Rite Aid as well as professional organizations such as the American Association of Dermatology and the Skin Cancer Foundation. Maurer also served internationally in various capacities at Beiersdorf in Germany, Sweden, Denmark, East Africa and Asia.

“I look forward to contributing to the leadership team of Establishment Labs. The achievements of the company to date demonstrate its innovative and entrepreneurial culture. We plan to continue to bring new products to market to expand the Motiva brand and drive long-term growth and value,” said Maurer. “There is an immense opportunity to provide plastic surgeons with truly innovative technologies, products and techniques to address patient concerns around the aesthetic look and feel of their procedure. These practices will have the potential to transform the cosmetic industry.”

Maurer holds a Master’s Degree in Marketing and Controlling from IPAG in Paris and graduated from Lycee Phillibert Dessaignes in Blois, France with a Baccalaureate C (A-Level) in Mathematics and Physics.

About Establishment Labs:
Establishment Labs is a global, privately held, medical technology company with a strong emphasis on innovation that designs, develops, manufactures and markets an innovative product portfolio. Its CE-marked Motiva Implants® line of silicone breast implants (http://www.motivaimplants.com) utilizes ultra-high purity medical-grade silicone and is subject to the strictest quality assurance testing throughout the manufacturing process. Motiva Implants® are sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field and is used in hospitals and clinics around the world. Divina® is a proprietary 3D imaging technology for full integration in consultation and surgical planning of unique solutions for breast aesthetics and reconstruction. All manufacturing facilities are fully compliant with both FDA and ISO applicable standards.

Establishment Labs Announces Certification of its Second Facility in Costa Rica

Second manufacturing facility in Costa Rica has received certification and begun shipping units to Europe and around the world. This new site, in combination with the company’s existing facility, extends manufacturing capacity by 4X and enables the company to expand its distribution capability.

NEW YORK, NY (PRWEB) JUNE 02, 2017

Establishment Labs, a global medical device company focused on aesthetic technologies with a strong emphasis on product development and innovation, announced today that its second manufacturing facility in Costa Rica has received its EC Certificate – Full Quality Assurance System from BSI and has begun shipping units from the new facility to Europe and around the world. This new site, in combination with the company’s existing facility, extends manufacturing capacity by 4X and enables Establishment Labs to expand its distribution capability.

“Full Quality Assurance System certification of our new, state-of-the-art facility is an important milestone, as it not only reinforces the high quality standards of our entire organization, but also meaningfully increases manufacturing capacity, and enables us to fully supply expanding demand,” said Juan José Chacón-Quirós, CEO and founder of Establishment Labs. “This certification is instrumental to our long-term strategic plans, provides compliance with key regulatory authorities, and adds significantly more flexibility to our current manufacturing and distribution operations. Our focus on product quality, state-of-the-art facilities, and deep technological know-how continues to establish and maintain our brand of consistency, quality and safety,” concluded Chacón-Quirós.

“Designed and built with advanced, environmentally beneficial techniques, the building’s infrastructure is supported by systems that are sustainable, renewable, and cost effective over the long term, such as a solar and battery microgrid, as well as an ice bank system that supports the clean room air systems,” said Salvador Dada, Chief Operating Officer. “These were important considerations for us, and I am pleased that we were able to build a modern, environmentally friendly facility that meets the highest quality of standards.”

The 40,000-square foot complex was completed in December 2016 and will serve as the company’s corporate headquarters, hosting more than 300 people, including manufacturing, research & development, regulatory affairs, finance, customer service, and other operational functions. The facility is located in the Coyol Free Zone of Costa Rica, considered the largest and most modern high-tech business park in Central America, hosting medical device companies including Abbott, Medtronic, Philips, Smith & Nephew, and Cooper Vision, among others.

About Establishment Labs:
Establishment Labs is a global, privately held, medical technology company with a strong emphasis on innovation that designs, develops, manufactures and markets an innovative product portfolio. Its CE-marked Motiva Implants® line of silicone breast implants (http://www.motivaimplants.com) utilizes ultra-high purity medical-grade silicone and is subject to the strictest quality assurance testing throughout the manufacturing process. Motiva Implants® are sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field and is used in hospitals and clinics around the world. Divina® is a proprietary 3D imaging technology for full integration in consultation and surgical planning of unique solutions for breast aesthetics and reconstruction. All manufacturing facilities have been successfully inspected according to the MDSAP program for compliance with 8 of the most stringent standards and regulations, including ISO 13485 and FDA 21 CRF Parts 820 and 821.

Establishment Labs Expands Management Team with Key Addition in Quality Assurance and Regulatory Affairs

NEW YORK, NY (PRWEB) MAY 26, 2017

Establishment Labs, a global medical device company focused on aesthetic technologies with a strong emphasis on product development and innovation, announced today the expansion of its leadership team with the addition of Alberto Quesada as Vice President of Quality Assurance & Regulatory Affairs.

“We are pleased to add a senior executive with Alberto’s deep expertise during this exciting stage of our growth. His background and track record of achievement within high-profile healthcare companies, such as Boston Scientific and Allergan, will add great value as we expand,” said Juan José Chacón-Quirós, CEO and founder of Establishment Labs.
“Alberto’s drive for organizational excellence and standard of quality aligns perfectly with our goal of becoming a global leader in aesthetic and reconstructive devices technology, while improving patient safety through product innovation.”

Alberto Quesada brings more than two decades of experience in quality assurance, quality control, and regulatory affairs to Establishment Labs. He will lead all activities related to the design, manufacture and distribution of quality products with the highest industry standard, as well as compliance with the company’s Quality Management System and applicable regulations. In addition, Mr. Quesada will lead all regulatory aspects of the business to support appropriate and timely introduction of products as well as a continuous state of compliance with markets’ regulatory requirements.
“The current regulatory framework requires not only a best-in-class product but a methodical approach to continuously improve quality at all levels,” stated Mr. Quesada. “Our plan is to deepen our competitive advantages by building a stronger set of capabilities in our Quality Management System.”

Prior to joining Establishment Labs, Mr. Quesada served as a Quality Director and later as a Management Representative at Boston Scientific in Costa Rica. Previously, he spent nearly a decade with Allergan Corporation, where he served in senior quality management roles. He also held roles at Baxter Healthcare Corporation, Kativo Chemical Industries and GTE Sylvania. Mr. Quesada received his MBA from Universidad Estatal a Distancia (UNED), Costa Rica and his undergraduate degree in Industrial Engineering from the University of Costa Rica.

About Establishment Labs
Establishment Labs is a global, privately held, medical technology company with a strong emphasis on innovation that designs, develops, manufactures and markets an innovative product portfolio. Its CE-marked Motiva Implants® line of silicone breast implants (http://www.motivaimplants.com) utilizes ultra-high purity medical-grade silicone and is subject to the strictest quality assurance testing throughout the manufacturing process. Motiva Implants® are sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field and is used in hospitals and clinics around the world. Divina® is a proprietary 3D imaging technology for full integration in consultation and surgical planning of unique solutions for breast aesthetics and reconstruction. All manufacturing facilities are fully compliant with both FDA and ISO applicable standards.

Establishment Labs Announces Close of $18M Financing Round

The funding will be used primarily to support the international launch of Motiva Implants® and Puregraft® in new markets

NEW YORK, NY (PRWEB) APRIL 17, 2017

Establishment Labs, a global medical device company focused on breast surgery technologies with a strong emphasis on product development and innovation, announced today that it has closed an $18 million financing round. Multiple investors participated, including Kilowatt Capital and Florence Capital Advisors.
“We are thrilled with the enthusiasm of the investment community in this oversubscribed round of funding,” said Juan José Chacón Quirós, CEO of Establishment Labs. “This round of investment will support the process of launching Motiva Implants® and Puregraft® in some of the largest markets worldwide. We are grateful for the backing from our new and existing investors.”

According to Nick Lewin from Crown Predator Holdings, “Our new partners join Perceptive Advisors and JW Funds with the same shared vision of Establishment Labs bringing innovation to market in the surgical aesthetics field. The company continues to rapidly scale, and this investment provides us the opportunity to build for the future and help Establishment Labs continue its high level of growth.”

Over the last six months, Establishment Labs has received regulatory clearances in Russia, Australia, Saudi Arabia, Israel, Vietnam and Brazil -among others- and is currently in the process of scaling up production capacity at its new state of the art manufacturing plant in Costa Rica.

About Establishment Labs:
Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Its CE-marked Motiva Implants® line of silicone breast implants utilizes medical-grade silicone and is subject to rigorous quality assurance testing throughout the manufacturing process. Motiva Implants® are sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field. The Puregraft® technology is used in hospitals and clinics around the world and provides physicians with confidence and convenience in fat grafting surgical procedures.

About CPH:
Crown Predator Holdings (CPH) invests in early and growth stage companies with an interest in special situations that do not easily fit into traditional investment categories. CPH leads and co-invests in transactions across all industries, capital structures, and styles. Through an extensive and global network of relationships and support, CPH seeks to add value as partners, not just as investors. Founded in 2006 and based in New York City, CPH is a family office led investment firm.

Establishment Labs Announces Regulatory Clearances in Brazil

Establishment Labs Announces Regulatory Clearances in Brazil

NEW YORK, NY (PRWEB) MARCH 31, 2017

Establishment Labs, a global medical device company focused on breast surgery technologies with a strong emphasis on product development and innovation, announced today that it has received regulatory approval from the Brazilian National Health Surveillance Agency (ANVISA) to market Motiva Implants® and Puregraft®.

According to a survey by the International Society of Aesthetic Plastic Surgery (ISAPS), there were over 166,000 breast augmentation procedures performed in Brazil in 2015, the world´s second largest market after the United States. Having more than 5,500 board certified plastic surgeons, Brazil is also one of the largest markets for fat grafting with more than 110,000 procedures performed in face, breast and body contouring in 2015.

“Regulatory clearance to market Motiva Implants® and Puregraft® in Brazil is an exciting milestone for Establishment Labs,” said Juan José Chacón Quirós, Chief Executive Officer of Establishment Labs, “Brazilian surgeon interest and support has been very high pre-launch, and we’ve seen enough demand to validate our commercialization strategy for Motiva Implants® and Puregraft® through our own direct sales network.This commitment to Brazil should position our company as a leader in the Brazilian market.”

Establishment Labs had already received the GMP (Good Manufacturing Practices) certification from Brazil’s National Health Surveillance Agency (ANVISA) following an inspection and audit of its manufacturing facility in San José, Costa Rica. Brazil’s GMP regulations, which closely resemble the internationally recognized ISO 13485 standard, require medical device manufacturers to have a quality system for the design, manufacture, packaging, labeling and storage of their products. “We are pleased with the successful completion of the ANVISA clearance for our products and GMP certification, which is evidence of our commitment to produce innovative products in strict adherence to our quality system,” said Salvador Dada, Chief Operating Officer of Establishment Labs.

According to Eddie de Oliveira, Vice-President of Sales for Latin America, “We are honored to begin our sales efforts in one of the most dynamic aesthetic markets in the world. The Brazilian plastic surgeon is known for their skill, expertise and innovative surgical techniques. We hope to win their confidence with our advanced line of surgical products.”

About Establishment Labs:
Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Its CE-marked Motiva Implants® line of silicone breast implants utilizes medical-grade silicone and is subject to rigorous quality assurance testing throughout the manufacturing process. Motiva Implants® are sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field. The Puregraft® technology is used in hospitals and clinics around the world and provides physicians with confidence and convenience in fat grafting surgical procedures.

Establishment Labs Announces Opening of New Medical Device Manufacturing Facility

Investment of $16.5M in the new manufacturing facility will support its growing international market presence

NEW YORK, NY (PRWEB) DECEMBER 15, 2016

Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation,
announced today the opening of a state of the art silicone medical device manufacturing facility in Costa Rica.
Luis Guillermo Solís, President of Costa Rica, inaugurated the Manuel E. Chacon B. Center for Advanced Silicone Technologies, commenting, “The growth of Establishment Labs demonstrates the great capacity and skills of our people and is an incentive for other national companies to seek insertion and link with this sector. We are very pleased with this news.”
Establishment Labs invested $16.5M in the 40,570 square foot facility and is currently scheduled to begin commercial-scale production by early 2017. The investment in the new facility was financed by a $15M debt facility from Perceptive Advisors and from its own capital.
“This new facility will support a multi-year effort to increase our manufacturing capabilities alongside our existing facility in Costa Rica, and will help us to achieve even greater operational excellence,” said Juan José Chacón Quirós, CEO and founder of Establishment Labs. “This new facility will allow us to meet growing demand from current markets, as well as expected demand as we enter new markets. As we develop our commercial footprint globally, we expect to increase customer responsiveness, improve inventory turns, and support our commercialization time and R&D efforts.”
According to Salvador Dada, COO of Establishment Labs, “at capacity, the new facility is expected to employ approximately 350 full-time, high-tech positions, including engineers and skilled operators, as well as process development and validation specialists who will work with the company´s research, development, and innovation teams to optimize and accelerate product launches. This new facility will house state-of-the-art equipment, including a fully equipped 3D lab as well as 16,000 square feet of ISO Class VII clean-room operations.”
About Establishment Labs:
Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Its CE-marked Motiva Implants® line of silicone breast implants utilizes medical-grade silicone and is subject to rigorous quality assurance testing throughout the manufacturing process. Motiva Implants are sold in approximately 50 countries worldwide.
About Perceptive Advisors:
Founded in 1999, Perceptive Advisors is focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare. Its dedicated team of industry experts uses a unique balance of scientific, technical and investment expertise to identify opportunities. Perceptive seeks to evaluate opportunities without biases by analyzing and weighing critical data and catalysts assessing the balance between market perception and reality. Perceptive manages approximately $2 billion across our strategies and has a long and successful track record.

New Technology by Establishment Labs Results in Increased Safety for Patients Seeking Breast Augmentation

Patient centric innovation is cornerstone of new Safety Campaign

NEW YORK, NY (PRWEB) OCTOBER 17, 2016

Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation, today announced the launch of the Motiva Safety Campaign featuring Motiva Implants® with Q Inside Safety Technology™. The campaign will focus on tools that empower women to be in charge of their health through advanced technology and enhanced warranty options.

“Our mission is to make breast aesthetics safer and better for women worldwide by delivering a world class technology platform that promotes women’s health and lifestyle choices,” said Juan José Chacón-Quirós, CEO of Establishment Labs. “We are constantly evaluating and expanding our program to allow women to be in control of their health by leveraging the most advanced tools and warranty options available in breast aesthetics.”
The cornerstone of the safety campaign is the Q Inside Safety Technology™, a biosensor that is accessed via a proprietary handheld reader when waved over the breast area. This easy method allows doctors to non-invasively retrieve specific information on each implant, even years from now when patients may have misplaced their paperwork.
Highlights of the technology are:
World’s first FDA-cleared and CE-approved biosensor solution that allows plastic surgeons to connect patients through both the MotivaImagine™ App and the Motiva website (MotivaImplants.com)
Q Inside Safety Technology™ is an electronic passport containing all relevant information about implants

Increased peace of mind in the unlikely event of a safety issue or device recall
Helps ensure patient safety and well-being Non-invasive verification of its unique electronic serial number within the body
15-digit serial number delivered to the reader corresponds with a secure, online database that can be accessed only via the Internet by authorized persons
Another unique benefit for patients is the ability to register their implants via an App,

MotivaImagine™. The App will:
Store their serial number to ensure it is always available
Offer the opportunity for an extended warranty which not only covers the replacement cost of the implants, but also offers financial assistance applicable to revision surgery costs
Provide reminders concerning breast health
Dr. Marcos Sforza, Plastic Surgeon at The Hospital Group states, “Our patient’s safety is our top priority. In the United Kingdom, thousands of women suffered the stress of not knowing the information of their implants when a French manufacturer had a troubling market recall. Therefore, we now only offer Motiva Implants® with Q Inside Safety Technology™ as it provides our patients control and verification of their implant for their safety and well-being.”.

“Motiva’s Q Inside Safety Technology™ offers patients a safety benefit, unlike any other breast implant in the world. I look forward to the time when we will be able to utilize the Motiva Implants in the United States,” said Scott Spear, MD, Plastic Surgeon, Washington DC.

About Establishment Labs:
Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implants® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

Establishment Labs and Puregraft Announce Strategic Partnership

An exclusive international distribution transaction marries advanced breast implants and autologous fat transfers

NEW YORK, NY (PRWEB) SEPTEMBER 14, 2016

Establishment Labs, a global medical device company focused on next-generation breast implants and other innovative medical device technologies, announced today that it has entered into an exclusive agreement to distribute Puregraft’s® line of autologous fat transfer products. The agreement also includes an additional option to distribute the Puregraft® products in the United States and Canada.

“We are very proud of this partnership with Puregraft®, a brand that has been at the cutting edge of technology in cell therapies,” said Juan José Chacón Quirós, Chief Executive Officer of Establishment Labs. “Puregraft® autologous fat transfer has demonstrated long term natural tissue retention, and will enable advanced cell-and-implant hybrid aesthetic and reconstructive treatments in combination with our innovative line of Motiva Implants®. We believe that incorporating the latest technologies into breast aesthetics, breast reconstruction and body contouring will improve patient outcomes significantly and we are continuing to invest to bring an entirely new generation of products and therapies to market.”

Used in combination, Motiva Implants® and Puregraft® autologous fat transfer allows plastic surgeons to balance volume between silicone breast implants and subcutaneous tissue volume, for a more natural look and feel using the patient’s own cells.
“We are delighted to work with Establishment Labs to advance the state of the art Plastic Surgery procedures,” said Brad Conlan, CEO of Puregraft, and LLC. “We are enthusiastic about the opportunities in the international market, and anticipate that hybrid procedures will become the new standard for breast augmentation, breast reconstruction and body contouring.”

“There is a critical, unmet need in breast aesthetics and breast reconstruction surgery for consistent, reproducible treatments using silicone implants in combination with purified fat grafts in breast and body contouring. These are both best-of-breed companies in their respective fields,” said Professor Marcos Sforza, one of the leading voices in combination techniques and advanced technologies in Plastic Surgery. “This partnership will provide surgeons with additional tools and elevate the standard of care for patients.”

About Establishment Labs:
Establishment Labs is an innovator in implantable medical devices. Their Motiva Implants® line of silicone breast implants are approved for sale in over 60 countries.
Motiva Implants® combine several proprietary technologies to improve safety and patient satisfaction, including SilkSurface® hierarchical micro-nano structures, Ergonomix™ the world’s first breast implant with ergonomic characteristics, and the QInside™ RFID microtransponder technology. QInside™ is- also cleared for sale in the U.S. via FDA’s 510(k) pathway. Establishment Labs manufactures its own products in state-of-the-art ISO 13485-certified facilities.

About Puregraft:
Puregraft, LLC is a global medical device company owned by Bimini Technologies. In 15 minutes or less, Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field. The Puregraft® technology is used in hospitals and clinics around the world and provides physicians with confidence and convenience. Puregraft, LLC is positioned to continue its leadership in the rapidly expanding, fat transfer marketplace. The company was founded in 2013 and is based in San Diego, California.

Establishment Labs Announces Completion of a $28 Million Financing

NEW YORK, NY (PRWEB) JULY 20, 2016

Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation, announced that existing investors exercised their option to invest an additional $6.84 Million, completing a $28 Million financing. Investors in the financing include Crown Predator Holdings (CPH), JW Funds, and Perceptive Advisors.

“This additional investment allows us to continue our rapid pace of innovation and commercialization,” said Juan José Chacón Quirós, CEO of Establishment Labs, “as well as complete our new GMP compliant, state of the art facility. This facility quadruples our production capacity, and readies us for regulatory clearance in the United States.”

“Less than a year after our original investment, the exercise of our investor option shows our confidence in the management team and the business,” said Nick Lewin, Partner at CPH. “There is a real opportunity to be the market leader, not only in patient satisfaction and safety, but also in sales volume, and transform the market in the process.”

According to Jason Wild, Founder and Chief Investment Officer of JW Asset Management, LLC, “Establishment Labs is quickly becoming the premier company in Breast Aesthetics, as they continue to innovate with the best minds in biomedical engineering and Plastic Surgery. The rapid industry acceptance and usage by key opinion leaders, scientists, and surgeons shows that Establishment Labs has figured out how to make a meaningful difference in this industry.”

Joseph Edelman, Chief Executive Officer and Portfolio Manager of Perceptive Advisors added, “This investment is based not only on what Establishment Labs has accomplished but what we believe they are going to accomplish in the future. Our diligence in the space suggests that Motiva-branded implants are a transformational product in the industry, and that Establishment Labs should become the outright market leader.

About Establishment Labs:
Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Utilizing only the highest quality of medical grade silicones, CE-marked Motiva Implants® are rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

About CPH:
Crown Predator Holdings (CPH) invests in early and growth stage companies with an interest in special situations that do not easily fit into traditional investment categories. CPH leads and co-invests in transactions across all industries, capital structures, and styles. Through an extensive and global network of relationships and support, CPH seeks to add value as partners, not just as investors. Founded in 2006 and based in New York City, CPH is a family office led investment firm.

About JW Asset Management, LLC:
JW Asset Management is a New York based fund manager for five investment partnerships. Jason Wild, a registered pharmacist, is the firm’s founder and chief investment officer. JW Asset Management has a strong history of finding opportunities within the specialty pharmaceutical sector. The firm is active in both the public and private equity markets.

About Perceptive Advisors:
Founded in 1999, Perceptive Advisors is focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare. Our dedicated team of industry experts uses a unique balance of scientific, technical and investment expertise to identify opportunities. Perceptive seeks to evaluate opportunities without biases by analyzing and weighing critical data and catalysts assessing the balance between market perception and reality. Perceptive manages approximately $2 billion across our strategies and has a long and successful track record.

Establishment Labs Receives Korean Regulatory Approval for Motiva Implants

Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation, announced today that it has received approval from the Korean Food & Drug Administration (KFDA). Establishment Labs also announced a 10 year distribution agreement with Seoul-based Human Wellness Corporation (HWC) to market Motiva Implants® and the MotivaImagine™ platform, combining the latest breast implant technology with integrated 3D capabilities and the latest surgical and consultation tools.

“I am thrilled to announce approval from the KFDA for Motiva Implants®,” said Juan José Chacón Quirós, Founder and Chief Executive Officer of Establishment Labs, “This is a crucial step in Establishment Labs becoming the worldwide market leader in breast implant technology. Given the product safety record, Motiva Implants® have quickly become the breast implants of choice for patients who are seeking the most advanced devices for breast aesthetics.”

“As we expand to new markets globally,” Mr. Chacón Quirós added, “we will continue to invest in research and development, intellectual property and clinical studies that create innovative product and platform technologies. South Korea is a very important market for both us and the industry, and I expect we will have continued regulatory approvals globally throughout this year.”

Worldwide, there have been over 150,000 implantations performed with Motiva Implants® with an unparalleled safety record. Motiva Implants® are available with the Q Inside Safety Technology™, an FDA cleared and CE approved RFID solution that allows Plastic Surgeons to connect patients through the MotivaImagine™ App to an electronic passport that contains all of the relevant information about their breast implants for increased safety and peace of mind.

According to John Lim, Chairman of HWC, “Korea is the largest market for breast aesthetics in Asia. We are honored to be the long term partner of Establishment Labs, with a mission of bringing next generation breast implant technology to Korean women. With KFDA clearance, we believe that Motiva Implants® and MotivaImagine™ will provide best-in-class technology for the sophisticated Korean consumer.”
The KFDA approval in Korea is the most recent of regulatory clearances for Motiva Implants®, adding to its existing regulatory approvals in over 60 countries worldwide.

About Establishment Labs:
Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implants® line is rigorously scrutinized by professional quality engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.